CLINICAL EVALUATION OF A NEW ANTIMETABOLITE, 6-MERCAPTOPURINE, IN THE TREATMENT OF LEUKEMIA AND ALLIED DISEASES
CLINICAL EVALUATION OF A NEW ANTIMETABOLITE, 6-MERCAPTOPURINE, IN THE TREATMENT OF LEUKEMIA AND ALLIED DISEASES
复制标题
DOI：
10.1182/blood.v8.11.965.965
复制
发表时间：
1953-01-01
期刊：
影响因子：
20.3
通讯作者：
RHOADS, CP
中科院分区：
文献类型：
--
作者：
BURCHENAL, JH;MURPHY, ML;RHOADS, CP
抗代谢药(嘌呤拮抗剂)6-巯基嘌呤对45例儿童急性白血病中的15例和少数成人早、晚期慢性粒细胞白血病有良好的血液学和临床缓解作用。在一些对氨甲喋呤、ACTH和可的松耐药的儿童中，它的使用情况有所改善。儿童的剂量为2.5毫克。每公斤。中毒的特征是胃肠道症状或骨髓抑制。淋巴瘤、肉瘤和癌症没有改善。
An antimetabolite (purine antagonist) 6-mercaptopurine produced good hematologic and clinical remissions in 15 of 45 children with acute leukemia and in a few cases of early and late stages of chronic myelogenous leukemia in adults. Improvement followed its use in some children resistant to amethopterin, ACTH and cortisone. The dose in children was 2.5 mg. per kilo. Poisoning was characterized by gastrointestinal symptoms or bone marrow depression. No improvement was noted in lymphomas, sarcomas and carcinomas.